0001193125-23-230628.txt : 20230907 0001193125-23-230628.hdr.sgml : 20230907 20230907160531 ACCESSION NUMBER: 0001193125-23-230628 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230901 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20230907 DATE AS OF CHANGE: 20230907 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vaxcyte, Inc. CENTRAL INDEX KEY: 0001649094 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 464233385 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39323 FILM NUMBER: 231242281 BUSINESS ADDRESS: STREET 1: 825 INDUSTRIAL ROAD, STE. 300 CITY: SAN CARLOS STATE: CA ZIP: 94070 BUSINESS PHONE: 650-837-0111 MAIL ADDRESS: STREET 1: 825 INDUSTRIAL ROAD, STE. 300 CITY: SAN CARLOS STATE: CA ZIP: 94070 FORMER COMPANY: FORMER CONFORMED NAME: SutroVax, Inc. DATE OF NAME CHANGE: 20150724 8-K 1 d452686d8k.htm 8-K 8-K
false 0001649094 0001649094 2023-09-01 2023-09-01

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 1, 2023

 

 

Vaxcyte, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   01-39323   46-4233385

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

825 Industrial Road  

Suite 300

San Carlos, California

  94070
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: 650 837-0111

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $0.001 par value per share   PCVX   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


Item 1.01 Entry into a Material Definitive Agreement.

On September 1, 2023, Vaxcyte, Inc. (the “Company”) entered into an assignment and assumption of lease agreement (the “Assignment Agreement”) with Codexis, Inc. (the “Assignor”) for the purposes of expanding the Company’s headquarters located at 825 Industrial Road in San Carlos, California (the “Building”). Under the Assignment Agreement, the Company shall assume all of Assignor’s rights, title and interest as “Tenant” under that certain lease agreement dated January 29, 2021 (the “Lease”) by and between Assignor and ARE-San Francisco No. 63, LLC (the “Landlord”) covering approximately 36,593 rentable square feet of the Building (the “Premises”). The Landlord has consented to the assignment and assumption of the Lease.

The term of the Lease commenced on November 30, 2021 (the “Commencement Date”) and will expire November 30, 2031 (the “Term”) unless earlier terminated.

Under the Lease, the base rent is abated for three full calendar months after the Effective Date of the Assignment Agreement (the “Abatement Period”). The “Effective Date” of the Assignment Agreement is triggered by the completion of various obligations of the parties which are customary for lease transactions of this nature, and is expected to be on or about October 1, 2023. Following the expiration of the Abatement Period, the Company will pay a monthly base rent for the Premises at an initial monthly rate of $5.85 per rentable square foot increasing by 3% per year on each annual anniversary of the Commencement Date for the Term of the Lease. The Company shall not have any right to expand the Premises or extend the Term of the Lease; provided, however, the Company may extend the Term of the Lease for a period of five years so long as (i) the Landlord consents to the assignment of such extension right pursuant to the Landlord’s consent; and (ii) the Landlord agrees that Assignor shall be released from all liability and obligations under the Lease during said extension term.

Throughout the term of the Lease, the Company is responsible for paying certain costs and expenses, in addition to the rent, as specified in the Lease, including maintenance costs, taxes and operating expenses. The Lease includes various covenants, indemnities, defaults, termination rights and other provisions customary for lease transactions of this nature. The Company will provide the Landlord a security deposit in the amount of a $220,655.79 letter of credit to secure the performance of the Company’s obligations under the Lease.

As reported by the Company on Form 8-K filed on January 25, 2021, the Company previously entered into a separate lease agreement with the Landlord (the “Original Lease”) for the purpose of establishing the Company’s new corporate headquarters at the Building. Under the Original Lease, the Company leases 77,734 rentable square feet of the Building. The Company has entered into this Assignment Agreement for purposes of expanding its headquarters at the Building.

The foregoing is a summary description of certain terms of the Lease and does not purport to be complete, and it is qualified in its entirety by reference to the full text of the Assignment Agreement and related written consent of the Landlord, each to be filed as an exhibit to our Quarterly Report on Form 10-Q for the quarter ended September 30, 2023.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

      VAXCYTE, INC.
Date: September 7, 2023     By:  

/s/ Andrew Guggenhime

      Andrew Guggenhime
      President and Chief Financial Officer
EX-101.SCH 2 pcvx-20230901.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 pcvx-20230901_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 pcvx-20230901_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document and Entity Information
Sep. 01, 2023
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001649094
Document Type 8-K
Document Period End Date Sep. 01, 2023
Entity Registrant Name Vaxcyte, Inc.
Entity Incorporation State Country Code DE
Entity File Number 01-39323
Entity Tax Identification Number 46-4233385
Entity Address, Address Line One 825 Industrial Road
Entity Address, Address Line Two Suite 300
Entity Address, City or Town San Carlos
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94070
City Area Code 650
Local Phone Number 837-0111
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.001 par value per share
Trading Symbol PCVX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 6 d452686d8k_htm.xml IDEA: XBRL DOCUMENT 0001649094 2023-09-01 2023-09-01 false 0001649094 8-K 2023-09-01 Vaxcyte, Inc. DE 01-39323 46-4233385 825 Industrial Road Suite 300 San Carlos CA 94070 650 837-0111 false false false false Common Stock, $0.001 par value per share PCVX NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( *^ )U<'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " "O@"=7,O3 />\ K @ $0 &1O8U!R;W!S+V-O&ULS9)1 M2\,P$,>_BN2]O31%9:'+BV-/"H(#Q;>0W+9@TX;DI-VW-ZU;A^@'\#%W__SN M=W"-"=+T$9]C'S"2PW0S^K9+TH0U.Q(%"9#,$;U.94YTN;GOH]>4G_$ 09L/ M?4 0G-^!1])6DX8)6(2%R%1CC301-?7QC+=FP8?/V,XP:P!;]-A1@JJL@*EI M8CB-;0-7P 0CC#Y]%] NQ+GZ)W;N #LGQ^26U# ,Y5#/N;Q#!6]/CR_SNH7K M$NG.8/Z5G*13P#6[3'ZM'S:[+5."B[K@JX+?[P27_%:*U?OD^L/O*NQ[Z_;N M'QM?!%4#O^Y"?0%02P,$% @ KX G5YE&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" "O@"=7-0'YX%<$ I$0 & 'AL+W=O/L> MV<2F6W/,#5C&Y_7$U&,C>Q2/E<$9TG"5.'.Q[+ MW=BASL>-%['9&GO#G8PRMN$+;G[/Y@I:;J42B82G6LB4*+X>.U-Z>^?W;$#Q MQ*O@.WUR36Q75E*^V<93-'8\2\1C'AHKP>#KG<]X'%LEX/CG*.I4[[2!I]]GA"^H^ ),?3*%T8N*$7R,V::)#H]?LUAS MA*-;<711G6/N9D"B6 PYC/B>?.*')B)I56#U4K*JOY2'C M32QX^.#Z$P+1KR#ZET',N1+2UGE$8+8T\N!*1747Y=U6WS<5V\TE>7OA&V$K M'""?6=)(ANN\LGUX,/P*,A]V$*Y!Q36XA O4I,JD*MR + R,&IG)'(H,:DU& MC:"X\/T#0C>LZ(:7T#V*F)/G/%EQU02":WCT.A@&:!*I5]NH=PG0DNW)4P2E M)M8B+,?L/%Z+9+=_W?6#(!CT,,(3HZ>7$$ZC"$Q07WU\!9[8E M%5G*7?.2B1ALVIQC5G4PRM7@TH M[N??H\VE-E Y?XKLK)NT* Z[W@V:U'J1H+BW%TFUV M:+T 4-R]%S(6H3 BW9 O4-[6@!IY<)4V'K]> 'S>*%\/#87Z5&Q[8%\+. M]>MZW9R_%KU6LMKX?=RE_T?VI'4.9*V N&PKX,D.O\6;>9@K._FHOR)+8>+& MR=SU#XRD]GH?]^5J[![VX9:E&WYV^]@B]#Q=W$]_PYAJD_QS:')W3VZNT=W)YFN M6W>2_.'(N2.]DKK=T*-SS?LD:0]'KEC[SC1<>Z0R5C'G55LG;6,Y*UMP4C)9 MWMQDB6)"TV*M.W6G7$L.IM-N0V]H4JPKH\^6E :#7\H4)X],;NB62;&W8EC+ ME)"G8%Z"X6"DL<1Y*GQ#%V!IGP*\"!JP'.,HH8T%8Q(RA._]N/P9,&FM5X64 M,\$E#89BW3#GN-5W7AD6#\87$!GEW:GQ#&O+3HOE+3T[##\^R=[8DMLYS8). MIF(M>05TK*B/\.M,DP#HG%%>* 6KC68#A\EC%'S8 Y?R 5KXK;J*W5B'_2^ MFO-CT1=X=-8T\O1!BEHK'O;^RPF+-9O\R-%8\>2SP:0)P:?EA M6;/CO9NFJ:]PSLM_D/.?K7/--;=,7I+VH_\W5_DMC)/Q]%PZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\ M3;,,J^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4 MKS4@\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0ERHY_U=3_ 10 M2P,$% @ KX G5Y>*NQS $P( L !?3T\$MP>:4#M M.*2VBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3 MY?YVX$G1H2)8%II%R=.B':5_'FR-9V87YTC'?8Q']>5=2(6NF9MYEJ6R!F_236P@R*2*Y U+2X3[+O,&@EXN1:T/9=1,92L88!.R '<(Y_A M^[<#K3P&]'@!6^AC(,=D",Y1]XVXG\-/O4(VSV M'T:$%'J6"V&%E+C?Z/F-:#R!+ ]=R_$)'0.M#,,SQ;;!<.AHQ$5V9://8:Q# MB'/Z3XRQJK"$52Q;#X&'' E<)S"D&IND53 >"CVN*!.L>@PL(:EU&*ADMW,J MI]=V<,TB]RI#FJ,,:&T'X:-:"Q4&L&]R( DNR94;4EWI>::W=Y-[2:AU[D&P M]_ :C1W-CQ^W_ %02P,$% @ KX G5R0>FZ*M ^ $ !H !X;"]? M+7_OR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2* M+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\ M7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7 M-_=%KLWC":[?#'!X=/X!4$L#!!0 ( *^ )U=ED'F2&0$ ,\# 3 M6T-O;G1E;G1?5'EP97-=+GAM;*V334[#,!"%KQ)E6R4N+%B@IAM@"UUP 6-/ M&JO^DV=:TMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#HG?78E!U1?!0"50=.8ATB M>*ZT(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4Z]4SM')OJ7CI>1M-\$V9P&)9 M/(W"S&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N6%"*JX1<^1UPZGL[0$I&0[&1 MB5ZE8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ R!GZ]%T,4TFGC",S[O9 M_,%F"LC*30H1.;$$?\>=(\G=560C2&2FKW@ALO7L^T%.6X.^D\ K @ $0 @ &O M 9&]C4')O<',O8V]R92YX;6Q02P$"% ,4 " "O@"=7F5R<(Q & "< M)P $P @ '- 0 >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 M Q0 ( *^ )U&PO7BKL

&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0 M2P$"% ,4 " "O@"=799!YDAD! #/ P $P @ &Q$@ I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" #[$P ! end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.vaxcyte.com//20230901/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d452686d8k.htm pcvx-20230901.xsd pcvx-20230901_lab.xml pcvx-20230901_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d452686d8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "d452686d8k.htm" ] }, "labelLink": { "local": [ "pcvx-20230901_lab.xml" ] }, "presentationLink": { "local": [ "pcvx-20230901_pre.xml" ] }, "schema": { "local": [ "pcvx-20230901.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "pcvx", "nsuri": "http://www.vaxcyte.com/20230901", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d452686d8k.htm", "contextRef": "duration_2023-09-01_to_2023-09-01", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.vaxcyte.com//20230901/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d452686d8k.htm", "contextRef": "duration_2023-09-01_to_2023-09-01", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vaxcyte.com//20230901/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vaxcyte.com//20230901/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vaxcyte.com//20230901/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vaxcyte.com//20230901/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vaxcyte.com//20230901/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vaxcyte.com//20230901/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vaxcyte.com//20230901/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vaxcyte.com//20230901/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vaxcyte.com//20230901/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vaxcyte.com//20230901/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vaxcyte.com//20230901/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vaxcyte.com//20230901/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vaxcyte.com//20230901/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vaxcyte.com//20230901/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vaxcyte.com//20230901/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vaxcyte.com//20230901/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vaxcyte.com//20230901/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vaxcyte.com//20230901/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vaxcyte.com//20230901/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vaxcyte.com//20230901/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vaxcyte.com//20230901/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vaxcyte.com//20230901/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vaxcyte.com//20230901/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 13 0001193125-23-230628-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-230628-xbrl.zip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end